Trial reportClinical oral investigations2026
Efficacy of injectable platelet-rich fibrin associated with particulated deproteinized bovine bone mineral in horizontal maxillary regeneration - a randomized, triple blinded, split-mouth controlled clinical trial.
Trial report in Clinical oral investigations, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the efficacy of deproteinized bovine bone mineral (DBBM) associated with injectable platelet-rich fibrin (i-PRF) in horizontal maxillary regeneration. MATERIALS AND
methodsEdentulous maxillary patients indicated for horizontal bone regeneration prior to implant placement were included in a split-mouth randomized clinical trial. The tested bone grafts were: DBBM alone (Control group) and i-PRF + DBBM (i-PRF group). Bone width gain was measured with digital tomographs taken before surgery, 72 h after surgery, and 6 months postoperatively. Twelve months after implant placement, peri-implant bone changes were measured with periapical radiographs; keratinized tissue width, probing depth, plaque index, bleeding on probing, suppuration, and recession were evaluated. The implant success rate was also recorded. The data were submitted to two-way repeated measures analysis of variance (ANOVA) and Bonferroni's test (bone width and peri-implant bone changes), Student's t-test (peri-implant soft tissue), and Fisher's exact test (categorical data).
resultsA total of 18 patients were included in the study. Bone widths were significantly greater at the postsurgical and six-month timepoints compared with baseline for both graft techniques (p < 0.05). No significant differences were observed between control and i-PRF groups in bone width gain (p > 0.05), implant success (p = 0.510), peri-implant bone changes (p = 0.509), and outcomes of peri-implant soft tissues (p > 0.05).
conclusionThe association of DBBM with i-PRF showed similar outcomes compared with DBBM alone for the studied parameters. CLINICAL SIGNIFICANCE: In edentulous maxilla with insufficient bone width (≤ 4 mm), where cancellous bone is present, both the association of i-PRF+DBBM and DBBM alone were effective in providing bone width gain for implant placement. CLINICAL
trial registrationhttps//ensaiosclinicos.gov.br/rg/RBR10m7c788.
Indexed as
Identifiers
42489738What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.